{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:48:15Z","timestamp":1792900095346,"version":"4.5.0"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1038\/ajg.2013.138","type":"journal-article","created":{"date-parts":[[2013,5,7]],"date-time":"2013-05-07T08:03:36Z","timestamp":1367913816000},"page":"1268-1276","source":"Crossref","is-referenced-by-count":309,"title":["Opportunistic Infections With Anti-Tumor Necrosis Factor-\u03b1 Therapy in Inflammatory Bowel Disease: Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.14309","volume":"108","author":[{"given":"Alexander C","family":"Ford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20210210","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0140-6736(92)90999-J","article-title":"Tumour necrosis factor alpha in stool as a marker of intestinal inflammation.","volume":"339","author":"Braegger","year":"1992","journal-title":"Lancet"},{"key":"R2-12-20210210","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2249.1990.tb03334.x","article-title":"Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine.","volume":"81","author":"MacDonald","year":"1990","journal-title":"Clin Exp Immunol"},{"key":"R3-12-20210210","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/0016-5085(94)90398-0","article-title":"Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease.","volume":"106","author":"Breese","year":"1994","journal-title":"Gastroenterology"},{"key":"R4-12-20210210","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/gut.32.8.913","article-title":"Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease.","volume":"32","author":"Murch","year":"1991","journal-title":"Gut"},{"key":"R5-12-20210210","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1136\/gut.40.5.628","article-title":"Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alpha.","volume":"40","author":"Watkins","year":"1997","journal-title":"Gut"},{"key":"R7-12-20210210","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.biopha.2006.06.022","article-title":"Do anti-tumour necrosis factors induce response and remission in patients with refractory Crohns disease? A systematic meta-analysis of controlled clinical trials.","volume":"61","author":"Rahimi","year":"2007","journal-title":"Biomed Pharmacother"},{"key":"R8-12-20210210","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1365-2036.2009.03929.x","article-title":"Meta-analysis: the efficacy and safety of certolizumab pegol in Crohns disease.","volume":"29","author":"Shao","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"R9-12-20210210","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.cgh.2008.03.014","article-title":"Efficacy and safety of tumor necrosis factor antagonists in Crohns disease: meta-analysis of placebo-controlled trials.","volume":"6","author":"Peyrin-Biroulet","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R10-12-20210210","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2036.2006.03131.x","article-title":"Systematic review: infliximab therapy in ulcerative colitis.","volume":"25","author":"Gisbert","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"R12-12-20210210","first-page":"13","article-title":"Meta-analysis technique confirms the effectiveness of anti-TNF- in the management of active ulcerative colitis when administered in combination with corticosteroids.","volume":"13","author":"Rahimi","year":"2007","journal-title":"Med Sci Monit"},{"key":"R14-12-20210210","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/ajg.2011.73","article-title":"Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis.","volume":"106","author":"Ford","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"R15-12-20210210","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cgh.2010.09.016","article-title":"A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease.","volume":"9","author":"Kotlyar","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R16-12-20210210","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1053\/j.gastro.2008.01.012","article-title":"Risk factors for opportunistic infections in patients with inflammatory bowel disease.","volume":"134","author":"Toruner","year":"2008","journal-title":"Gastroenterology"},{"key":"R17-12-20210210","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"R18-12-20210210","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/ajg.2012.89","article-title":"A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease.","volume":"107","author":"Lichtenstein","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"R19-12-20210210","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1002\/ibd.20956","article-title":"Adalimumab safety in global clinical trials of patients with Crohns disease.","volume":"15","author":"Colombel","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"R20-12-20210210","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/ajg.2012.218","article-title":"Serious infection and mortality in patients with Crohns disease: more than 5 years of follow-up in the TREAT registry.","volume":"107","author":"Lichtenstein","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"R21-12-20210210","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.crohns.2009.02.010","article-title":", European Crohns and Colitis Organisation. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease.","volume":"3","author":"Rahier","year":"2009","journal-title":"J Crohns Colitis"},{"key":"R23-12-20210210","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials.","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"R24-12-20210210","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"et al. Measuring inconsistency in meta-analyses.","volume":"327","author":"Higgins","year":"2003","journal-title":"Br Med J"},{"key":"R25-12-20210210","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test.","volume":"315","author":"Egger","year":"1997","journal-title":"Br Med J"},{"key":"R26-12-20210210","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials.","volume":"343","author":"Sterne","year":"2011","journal-title":"Br Med J"},{"key":"R27-12-20210210","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohns disease: the CHARM trial.","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"R28-12-20210210","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":", for the SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohns disease.","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"R29-12-20210210","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":", the ACCENT I Study Group. Maintenance infliximab for Crohns disease: the ACCENT I randomised trial.","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"R30-12-20210210","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumour necrosis factor monoclonal antibody (adalimumab) in Crohns disease: the CLASSIC-I trial.","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"R31-12-20210210","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1053\/j.gastro.2005.03.003","article-title":"Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.","volume":"128","author":"Jarnerot","year":"2005","journal-title":"Gastroenterology"},{"key":"R32-12-20210210","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1053\/j.gastro.2006.02.014","article-title":", the Groupes Detudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Infliximab plus azathioprine for steroid-dependent Crohns disease patients: a randomized placebo-controlled trial.","volume":"130","author":"Lemann","year":"2006","journal-title":"Gastroenterology"},{"key":"R33-12-20210210","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohns disease.","volume":"340","author":"Present","year":"1999","journal-title":"N Engl J Med"},{"key":"R34-12-20210210","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/gut.52.7.998","article-title":"Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial.","volume":"52","author":"Probert","year":"2003","journal-title":"Gut"},{"key":"R35-12-20210210","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1053\/j.gastro.2008.10.051","article-title":"Infliximab prevents Crohns disease recurrence after ileal resection.","volume":"136","author":"Regueiro","year":"2009","journal-title":"Gastroenterology"},{"key":"R36-12-20210210","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/gut.2010.221127","article-title":"Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial.","volume":"60","author":"Reinisch","year":"2011","journal-title":"Gut"},{"key":"R37-12-20210210","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0016-5085(99)70332-X","article-title":"Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohns disease.","volume":"117","author":"Rutgeerts","year":"1999","journal-title":"Gastroenterology"},{"key":"R38-12-20210210","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis.","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"R40-12-20210210","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","article-title":", for the PRECISE I Study Investigators. Certolizumab pegol for the treatment of Crohns disease.","volume":"357","author":"Sandborn","year":"2007","journal-title":"N Engl J Med"},{"key":"R41-12-20210210","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","article-title":"Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.","volume":"146","author":"Sandborn","year":"2007","journal-title":"Ann Intern Med"},{"key":"R42-12-20210210","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohns disease: results of the CLASSIC II trial.","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut"},{"key":"R43-12-20210210","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.cgh.2011.04.031","article-title":"Certolizumab pegol for active Crohns disease: a placebo-controlled, randomized trial.","volume":"9","author":"Sandborn","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R44-12-20210210","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"R45-12-20210210","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00054725-200105000-00001","article-title":"Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.","volume":"7","author":"Sands","year":"2001","journal-title":"Inflamm Bowel Dis"},{"key":"R46-12-20210210","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohns disease.","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med"},{"key":"R47-12-20210210","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1053\/j.gastro.2005.06.064","article-title":", the CDP870 Crohns Disease Study Group. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohns disease.","volume":"129","author":"Schreiber","year":"2005","journal-title":"Gastroenterology"},{"key":"R48-12-20210210","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa062897","article-title":", for the PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for Crohns disease.","volume":"357","author":"Schreiber","year":"2007","journal-title":"N Engl J Med"},{"key":"R49-12-20210210","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumour necrosis factor for Crohns disease.","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"key":"R50-12-20210210","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.crohns.2011.07.013","article-title":", Study Investigators. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohns disease.","volume":"6","author":"Watanabe","year":"2012","journal-title":"J Crohns Colitis"},{"key":"R51-12-20210210","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1111\/j.1365-2036.2004.02285.x","article-title":"Intravenous CDP870, a pegylated Fab fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohns disease: an exploratory study.","volume":"20","author":"Winter","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"R52-12-20210210","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1053\/j.gastro.2008.05.061","article-title":"A randomized trial of methotrexate in combination with infliximab for the treatment of Crohns disease.","volume":"135","author":"Feagan","year":"2008","journal-title":"Gastroenterology"},{"key":"R53-12-20210210","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","article-title":", for the Belgian Inflammatory Bowel Disease Research Group and the North Holland Gut Club. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohns disease: an open randomised trial.","volume":"371","author":"DHaens","year":"2008","journal-title":"Lancet"},{"key":"R54-12-20210210","first-page":"S8","article-title":"Infliximab, azathioprine, or infliximab and azathioprine for treatment of moderate to severe ulcerative colitis: the UC SUCCESS trial.","volume":"5","author":"Panaccione","year":"2011","journal-title":"J Crohns Colitis"}],"container-title":["American Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ajg2013138.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2013138","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2013138.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.ovid.com\/00000434-201308000-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:46:06Z","timestamp":1786542366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000434-201308000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1038\/ajg.2013.138","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718016096.793484930","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.718016096.793479086","asserted-by":"object"}]},"ISSN":["0002-9270"],"issn-type":[{"value":"0002-9270","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]}}}